Introduction: Breast cancer is the most frequently diagnosed cancer among the women. Most commonly used chemotherapy regimen is Doxorubicin and Cyclophosphamide (AC) which carries significant risk of febrile neutropenia. The aim of the study is to identify the incidence of febrile neutropenia and its effects on the delivery of chemotherapy in patients receiving following AC chemoregimen without primary prophylaxis. Materials and Methods: We retrospectively analyzed the case records of the localized breast cancer patients who were treated with AC chemoregimen without primary prophylaxis for febrile neutropenia. Results: Between 2013 and 2017, a total of 231 cases received AC chemoregimen. A total of 14 (6.1%) patients were found to have febrile neutropenia. All patients were recovered by day 19 and no deaths were observed. Except for ECOG performance status ( P = 0.001) no significant association was found with age, co-morbidities, menopausal status, body surface area and stage of the cancer. There were no treatment delays or dose reductions because of febrile neutropenia. Conclusion: The incidence of FN with AC chemotherapy in breast cancer patients is relatively less in the present study. Routine primary prophylaxis is not recommended as this chemotherapy falls in to low risk category for FN but can be considered for patients with ECOG PS > 1. If the diagnosis of febrile neutropenia and institution of appropriate measures are prompt, FN did not affect the delivery of chemotherapy and thus compromise survival.

Background: Acute promyelocytic leukemia (APL) accounts for approximately 10% of acute myeloid leukemia(AML) cases in adults. With the advent of targeted therapy like all- trans retinoic acid (ATRA) and arsenic trioxide, survival rates have improved leading to cure in majority of patients. The present study was designed to analyze the outcomes in newly diagnosed APL. Aims and objectives: The primary objective of this study was to analyze overall survival and relapse rate in APL. Secondary objective was to study the parameters impacting outcomes in APL. Materials and methods: All newly diagnosed patients with APL between January 2005 and December 2017 were retrospectively analyzed. Diagnosis of APL was confirmed by demonstration of PML-RARA translocation by polymerase chain reaction or fluorescence in situ hydridization. Risk stratification was done using Sanz risk. Event free survival was defined as the time from diagnosis till relapse, death or lost to follow up. Overall survival was defined as time from diagnosis till death or lost to follow up. Statistical analysis was done using SPSS software, v.25. Overall survival curves were plotted using the Kaplan-Meier method. INCLUSION CRITERIA: All cases of APL diagnosed by morphology and confirmed by RT PCR (PML RARα) were included in this study. EXCLUSION CRITERIA: Age ≤ 18yrs Death within 72 hours of admission / not taken treatment Prior chemotherapy or radiotherapy for the treatment of malignancy. Results: Data of 1396 AML patients between 2005 and 2017 was collected, of which 190(13.6%) patients had APL. Of 190 patients, 111 patients who met inclusion and exclusion criteria were analyzed. The median age at presentation was 33 years (range,19-60). The male female ratio was 1.01:1. The median duration of symptoms at presentation was 15 days (range, 3-180). According to Sanz risk grouping, high, intermediate and low risk were seen in 48 (43.1%), 46 (42.4%), 17(14.5%) patients respectively. The baseline characteristics are tabulated in Table 1. Of 111 patients, 96 (86.5%) patients received induction chemotherapy with ATRA and daunorubicin and 15(13.5%) patients received ATRA and arsenic trioxide. Induction mortality was 23(20.7%). Eighty-eight (79%) patients survived induction chemotherapy, of which 87(98.8%) were in complete molecular remission (CMR) at the end of consolidation. At a median follow up of 30 months, the event free survival rate, overall survival rate and relapse rate were 72%, 74.7% and 9% respectively. The overall survival rate in low-intermediate and high-risk groups were 84.1% and 62.5% respectively. Of eight patients who relapsed, five patients received second line chemotherapy and attained second CMR (100%). On univariate analysis, the strongest predictors for OS were high risk and bcr3 variant(p=0.007, p=<0.001 respectively). On multivariate analysis, only high risk was significant for overall survival (p=0.02). Conclusion: Majority of APL patients were high risk at presentation. High risk and bcr3 variant had significant impact on survival outcome in APL. As relapse rates were low and second CMR can be achieved with salvage chemotherapy in majority of patients, improving induction outcomes will further improve survivals in APL. Disclosures No relevant conflicts of interest to declare.

No abstract

enrolled in the exercise program, however 5 patients withdrew consent before commencement. Reasons for withdrawal were health concern (n ¼ 2), distance to the hospital (n ¼ 1) and unspecified (n ¼ 2). The completion rate of the 12-week exercise program was 78.6% (11/14). Disease progression (n ¼ 2) was the main reason for early discontinuation. The adherence rate of the supervised exercise session was 78.1% (207/ 265) and there was no adverse event associated with the exercise training. Among participants in the exercise program, there was no significant change in skeletal muscle index from baseline to post-intervention (mean, 9.461.3kg/m 2 vs 9.461.2kg/m 2 , p ¼ 0.982). FACIT-fatigue scale was non-significantly improved after the exercise intervention (mean, 35.2610.4 vs 38.269.8, p ¼ 0.635). Conclusions: Exercise interventions appear to be feasible and safe in patients with advanced solid cancer and might have a role of preventing skeletal muscle loss without fatigue exacerbation during palliative chemotherapy. Legal entity responsible for the study: Young Saing Kim.

No abstract